Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

Open Access 01-02-2015 | Original Article

Development of the designed ankyrin repeat protein (DARPin) G3 for HER2 molecular imaging

Authors: Robert Goldstein, Jane Sosabowski, Maria Livanos, Julius Leyton, Kim Vigor, Gaurav Bhavsar, Gabriela Nagy-Davidescu, Mohammed Rashid, Enrique Miranda, Jenny Yeung, Berend Tolner, Andreas Plückthun, Stephen Mather, Tim Meyer, Kerry Chester

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 2/2015

Abstract

Purpose

Human epidermal growth factor receptor-2 (HER2) overexpression is a predictor of response to anti-HER2 therapy in breast and gastric cancer. Currently, HER2 status is assessed by tumour biopsy, but this may not be representative of the larger tumour mass or other metastatic sites, risking misclassification and selection of suboptimal therapy. The designed ankyrin repeat protein (DARPin) G3 binds HER2 with high affinity at an epitope that does not overlap with trastuzumab and is biologically inert. We hypothesized that radiolabelled DARPin G3 would be capable of selectively imaging HER2-positive tumours, and aimed to identify a suitable format for clinical application.

Methods

G3 DARPins tagged with hexahistidine (His₆) or with histidine glutamate (HE)₃ and untagged G3 DARPins were manufactured using a GMP-compatible Pichia pastoris protocol and radiolabelled with ¹²⁵I, or with ¹¹¹In via DOTA linked to a C-terminal cysteine. BALB/c mice were injected with radiolabelled G3 and tissue biodistribution was evaluated by gamma counting. The lead construct ((HE)₃-G3) was assessed in mice bearing HER2-positive human breast tumour (BT474) xenografts.

Results

For both isotopes, (HE)₃-G3 had significantly lower liver uptake than His₆-G3 and untagged G3 counterparts in non-tumour-bearing mice, and there was no significantly different liver uptake between His₆-G3 and untagged G3. (HE)₃-G3 was taken forward for evaluation in mice bearing HER2-positive tumour xenografts. The results demonstrated that radioactivity from ¹¹¹In-(HE)₃-G3 was better maintained in tumours and cleared faster from serum than radioactivity from ¹²⁵I-(HE)₃-G3, achieving superior tumour-to-blood ratios (343.7 ± 161.3 vs. 22.0 ± 11.3 at 24 h, respectively). On microSPECT/CT, ¹¹¹In-labelled and ¹²⁵I-labelled (HE)₃-G3 could image HER2-positive tumours at 4 h after administration, but there was less normal tissue uptake of radioactivity with ¹¹¹In-(HE)₃-G3. Preadministration of trastuzumab did not affect the uptake of (HE)₃-G3 by HER2-positive tumours.

Conclusion

Radiolabelled DARPin (HE)₃-G3 is a versatile radioligand with potential to allow the acquisition of whole-body HER2 scans on the day of administration.

Available only for authorised users

Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol. 2012;9:16–32. doi:10.1038/nrclinonc.2011.177.CrossRef

Ross JS. Breast cancer biomarkers and HER2 testing after 10 years of anti-HER2 therapy. Drug News Perspect. 2009;22:93–106. doi:10.1358/dnp.2009.22.2.1334452.PubMedCrossRef

Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–97. doi:10.1016/S0140-6736(10)61121-X.PubMedCrossRef

Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367:1783–91. doi:10.1056/NEJMoa1209124.PubMedCrossRef

Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31:3997–4013. doi:10.1200/JCO.2013.50.9984.PubMedCrossRef

Goldstein R, Sosabowski J, Vigor K, Chester K, Meyer T. Developments in single photon emission computed tomography and PET-based HER2 molecular imaging for breast cancer. Expert Rev Anticancer Ther. 2013;13:359–73. doi:10.1586/era.13.11.PubMedCrossRef

Turner NH, Di Leo A. HER2 discordance between primary and metastatic breast cancer: assessing the clinical impact. Cancer Treat Rev. 2013;39:947–57. doi:10.1016/j.ctrv.2013.05.003.PubMedCrossRef

Lindstrom LS, Karlsson E, Wilking UM, Johansson U, Hartman J, Lidbrink EK, et al. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J Clin Oncol. 2012;30:2601–8. doi:10.1200/JCO.2011.37.2482.PubMedCrossRef

Gancberg D, Di Leo A, Cardoso F, Rouas G, Pedrocchi M, Paesmans M, et al. Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol. 2002;13:1036–43.PubMedCrossRef

10.

Baselga J, Cortes J, Kim SB, Im SA, Hegg R, Im YH, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366:109–19. doi:10.1056/NEJMoa1113216.PubMedCrossRef

11.

Paik S, Kim C, Wolmark N. HER2 status and benefit from adjuvant trastuzumab in breast cancer. N Engl J Med. 2008;358:1409–11. doi:10.1056/NEJMc0801440.PubMedCrossRef

12.

Mortimer JE, Bading JR, Colcher DM, Conti PS, Frankel PH, Carroll MI, et al. Functional imaging of human epidermal growth factor receptor 2-positive metastatic breast cancer using 64Cu-DOTA-trastuzumab PET. J Nucl Med. 2013;55:23–9. doi:10.2967/jnumed.113.122630.PubMedCentralPubMedCrossRef

13.

Dijkers EC, Oude Munnink TH, Kosterink JG, Brouwers AH, Jager PL, de Jong JR, et al. Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther. 2010;87:586–92. doi:10.1038/clpt.2010.12.PubMedCrossRef

14.

Perik PJ, Lub-De Hooge MN, Gietema JA, van der Graaf WT, de Korte MA, Jonkman S, et al. Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2006;24:2276–82. doi:10.1200/JCO.2005.03.8448.PubMedCrossRef

15.

Sorensen J, Sandberg D, Sandstrom M, Wennborg A, Feldwisch J, Tolmachev V, et al. First-in-human molecular imaging of HER2 expression in breast cancer metastases using the 111In-ABY-025 affibody molecule. J Nucl Med. 2014;55:730–5. doi:10.2967/jnumed.113.131243.PubMedCrossRef

16.

Binz HK, Amstutz P, Kohl A, Stumpp MT, Briand C, Forrer P, et al. High-affinity binders selected from designed ankyrin repeat protein libraries. Nat Biotechnol. 2004;22:575–82. doi:10.1038/nbt962.PubMedCrossRef

17.

Boersma YL, Pluckthun A. DARPins and other repeat protein scaffolds: advances in engineering and applications. Curr Opin Biotechnol. 2011;22:849–57. doi:10.1016/j.copbio.2011.06.004.PubMedCrossRef

18.

Binz HK, Stumpp MT, Forrer P, Amstutz P, Pluckthun A. Designing repeat proteins: well-expressed, soluble and stable proteins from combinatorial libraries of consensus ankyrin repeat proteins. J Mol Biol. 2003;332:489–503.PubMedCrossRef

19.

Schilling J, Schoppe J, Pluckthun A. From DARPins to LoopDARPins: novel LoopDARPin design allows the selection of low picomolar binders in a single round of ribosome display. J Mol Biol. 2014;426:691–721. doi:10.1016/j.jmb.2013.10.026.PubMedCrossRef

20.

Dreier B, Pluckthun A. Rapid selection of high-affinity binders using ribosome display. Methods Mol Biol. 2012;805:261–86. doi:10.1007/978-1-61779-379-0_15.PubMedCrossRef

21.

Zahnd C, Kawe M, Stumpp MT, de Pasquale C, Tamaskovic R, Nagy-Davidescu G, et al. Efficient tumor targeting with high-affinity designed ankyrin repeat proteins: effects of affinity and molecular size. Cancer Res. 2010;70:1595–605. doi:10.1158/0008-5472.CAN-09-2724.PubMedCrossRef

22.

Zahnd C, Wyler E, Schwenk JM, Steiner D, Lawrence MC, McKern NM, et al. A designed ankyrin repeat protein evolved to picomolar affinity to Her2. J Mol Biol. 2007;369:1015–28. doi:10.1016/j.jmb.2007.03.028.PubMedCrossRef

23.

Jost C, Schilling J, Tamaskovic R, Schwill M, Honegger A, Pluckthun A. Structural basis for eliciting a cytotoxic effect in HER2-overexpressing cancer cells via binding to the extracellular domain of HER2. Structure. 2013;21:1979–91. doi:10.1016/j.str.2013.08.020.PubMedCrossRef

24.

Hofstrom C, Orlova A, Altai M, Wangsell F, Graslund T, Tolmachev V. Use of a HEHEHE purification tag instead of a hexahistidine tag improves biodistribution of affibody molecules site-specifically labeled with (99m)Tc, (111)In, and (125)I. J Med Chem. 2011;54:3817–26. doi:10.1021/jm200065e.PubMedCrossRef

25.

Hofstrom C, Altai M, Honarvar H, Strand J, Malmberg J, Hosseinimehr SJ, et al. HAHAHA, HEHEHE, HIHIHI, or HKHKHK: influence of position and composition of histidine containing tags on biodistribution of [(99m)Tc(CO)3](+)-labeled affibody molecules. J Med Chem. 2013;56:4966–74. doi:10.1021/jm400218y.PubMedCrossRef

26.

Sosabowski JK, Matzow T, Foster JM, Finucane C, Ellison D, Watson SA, et al. Targeting of CCK-2 receptor-expressing tumors using a radiolabeled divalent gastrin peptide. J Nucl Med. 2009;50:2082–9. doi:10.2967/jnumed.109.064808.PubMedCrossRef

27.

Waibel R, Alberto R, Willuda J, Finnern R, Schibli R, Stichelberger A, et al. Stable one-step technetium-99m labeling of His-tagged recombinant proteins with a novel Tc(I)-carbonyl complex. Nat Biotechnol. 1999;17:897–901. doi:10.1038/12890.PubMedCrossRef

28.

Dijkers EC, Kosterink JG, Rademaker AP, Perk LR, van Dongen GA, Bart J, et al. Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging. J Nucl Med. 2009;50:974–81. doi:10.2967/jnumed.108.060392.PubMedCrossRef

29.

Smith-Jones PM, Solit DB, Akhurst T, Afroze F, Rosen N, Larson SM. Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat Biotechnol. 2004;22:701–6. doi:10.1038/nbt968.PubMedCrossRef

30.

Reddy S, Shaller CC, Doss M, Shchaveleva I, Marks JD, Yu JQ, et al. Evaluation of the anti-HER2 C6.5 diabody as a PET radiotracer to monitor HER2 status and predict response to trastuzumab treatment. Clin Cancer Res. 2011;17:1509–20. doi:10.1158/1078-0432.CCR-10-1654.PubMedCentralPubMedCrossRef

31.

Perols A, Honarvar H, Strand J, Selvaraju R, Orlova A, Karlstrom AE, et al. Influence of DOTA chelator position on biodistribution and targeting properties of (111)In-labeled synthetic anti-HER2 affibody molecules. Bioconjug Chem. 2012;23:1661–70. doi:10.1021/bc3002369.PubMedCrossRef

32.

Orlova A, Tolmachev V, Pehrson R, Lindborg M, Tran T, Sandstrom M, et al. Synthetic affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors. Cancer Res. 2007;67:2178–86. doi:10.1158/0008-5472.CAN-06-2887.PubMedCrossRef

33.

Sosabowsky J, Melendez-Alafort L, Mather S. Radiolabelling of peptides for diagnosis and therapy of non-oncological diseases. Q J Nucl Med. 2003;47:223–37.PubMed

34.

Pruszynski M, Koumarianou E, Vaidyanathan G, Revets H, Devoogdt N, Lahoutte T, et al. Improved tumor targeting of anti-HER2 nanobody through N-succinimidyl 4-guanidinomethyl-3-iodobenzoate radiolabeling. J Nucl Med. 2014;55:650–6. doi:10.2967/jnumed.113.127100.PubMedCentralPubMedCrossRef

35.

Epa VC, Dolezal O, Doughty L, Xiao X, Jost C, Pluckthun A, et al. Structural model for the interaction of a designed ankyrin repeat protein with the human epidermal growth factor receptor 2. PLoS One. 2013;8:e59163. doi:10.1371/journal.pone.0059163.PubMedCentralPubMedCrossRef

36.

Boku N. HER2-positive gastric cancer. Gastric Cancer. 2014;17:1–12. doi:10.1007/s10120-013-0252-z.PubMedCentralPubMedCrossRef

37.

Wessels BW, Konijnenberg MW, Dale RG, Breitz HB, Cremonesi M, Meredith RF, et al. MIRD pamphlet No. 20: the effect of model assumptions on kidney dosimetry and response – implications for radionuclide therapy. J Nucl Med. 2008;49:1884–99. doi:10.2967/jnumed.108.053173.PubMedCrossRef

38.

Beylergil V, Morris PG, Smith-Jones PM, Modi S, Solit D, Hudis CA, et al. Pilot study of 68Ga-DOTA-F(ab’)2-trastuzumab in patients with breast cancer. Nucl Med Commun. 2013;34:1157–65. doi:10.1097/MNM.0b013e328365d99b.PubMedCentralPubMed

39.

Baum RP, Prasad V, Muller D, Schuchardt C, Orlova A, Wennborg A, et al. Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled affibody molecules. J Nucl Med. 2010;51:892–7. doi:10.2967/jnumed.109.073239.PubMedCrossRef

40.

Tolner B, Bhavsar G, Foster B, Vigor K, Chester K. Production of recombinant proteins from Pichia pastoris: interfacing fermentation and immobilized metal ion affinity chromatography. In: Gupta VK, Tuohy MG, O’Donovan A, editors. Laboratory protocols in fungal biology. Current methods in fungal biology. New York: Springer; 2013; p. 407–420CrossRef

41.

Han BH, Xiu QY, Wang HM, Shen J, Gu AQ, Luo Y, et al. A multicenter, randomized, double-blind, placebo-controlled safety study to evaluate the clinical effects and quality of life of paclitaxel-carboplatin (PC) alone or combined with endostar for advanced non-small cell lung cancer (NSCLC). Zhonghua Zhong Liu Za Zhi. 2011;33:854–9.PubMed

Title: Development of the designed ankyrin repeat protein (DARPin) G3 for HER2 molecular imaging
Authors: Robert Goldstein
Jane Sosabowski
Maria Livanos
Julius Leyton
Kim Vigor
Gaurav Bhavsar
Gabriela Nagy-Davidescu
Mohammed Rashid
Enrique Miranda
Jenny Yeung
Berend Tolner
Andreas Plückthun
Stephen Mather
Tim Meyer
Kerry Chester
Publication date: 01-02-2015
Publisher: Springer Berlin Heidelberg
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 2/2015
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-014-2940-2

At a glance: The STEP trials

Springer Medicine

Development of the designed ankyrin repeat protein (DARPin) G3 for HER2 molecular imaging

Abstract

Purpose

Methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2015

The value of 18F-fluoride PET/CT in the assessment of screw loosening in patients after intervertebral fusion stabilization

[68Ga]PSMA-HBED uptake mimicking lymph node metastasis in coeliac ganglia: an important pitfall in clinical practice

PET/CT before autologous stem cell transplantation predicts outcome in refractory/relapsed follicular lymphoma

Erratum to: The impact of nodal tumour burden on lymphoscintigraphic imaging in patients with melanomas

The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer

FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0